← Library
Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

FOXO4-DRI

Not FDA approved

Experimental senolytic peptide

Also known as: proxofim, FOXO4-DRI TFA salt form

Evidence score
21/ 100
Thin evidence

Very thin human evidence

  • Regulatory standing. Sold as a research chemical, not approved
  • Animal / preclinical only. Evidence is largely animal or in-vitro
  • No registered human trials. Nothing registered on ClinicalTrials.gov
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

FOXO4-DRI is a synthetic peptide made from D-amino acids in reversed order (a retro-inverso design), sometimes called proxofim. It is designed to interfere with the interaction between the FOXO4 protein and p53 inside senescent cells, which in lab studies can push those aging, non-dividing cells toward self-destruction. This makes it a candidate senolytic, meaning a compound intended to clear senescent cells.

What the evidence shows

Automatic summaryAnimal / preclinical

The evidence comes from cell and mouse studies, including a widely cited 2017 mouse study, and about 17 published papers in total. There are no registered human trials, so its safety and effects in people are unknown, and it is not approved for any use.

Key facts

Molecular formula
C228H388N86O64
Molecular weight
5358 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

0registered studies
Nonemost advanced phase
0completed (sample)
0recruiting (sample)

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

17papers referencing FOXO4-DRI

Cellular senescence in the aging and diseased kidney.

J Cell Commun Signal2018

Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.

Circulation2023

Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis.

JCI Insight2021

FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.

Aging (Albany NY)2020

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.